[go: up one dir, main page]

ES2194054T3 - Compuestos de lactona macrociclica y su procedimiento de produccion. - Google Patents

Compuestos de lactona macrociclica y su procedimiento de produccion.

Info

Publication number
ES2194054T3
ES2194054T3 ES95932876T ES95932876T ES2194054T3 ES 2194054 T3 ES2194054 T3 ES 2194054T3 ES 95932876 T ES95932876 T ES 95932876T ES 95932876 T ES95932876 T ES 95932876T ES 2194054 T3 ES2194054 T3 ES 2194054T3
Authority
ES
Spain
Prior art keywords
macrociclic
production procedure
lactone compounds
lactone
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932876T
Other languages
English (en)
Inventor
H Nishida
Y Yamauchi
T-Pfizer Phar Inagaki
Y Kojima
N Kojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2194054T3 publication Critical patent/ES2194054T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

ESTA INVENCION DESCRIBE UN PROCEDIMIENTO PARA PRODUCIR UN COMPUESTO DE LACTONA MACROCICLICA QUE INCLUYE CULTIVAR ACTINOPLANES SP. FERM BP - 3832, EN PRESENCIA DE L - PROLINA, L HIDROXIPROLINA O ACIDO L - NIPECOTICO, Y DESPUES AISLAR UN COMPUESTO DE LACTONA MACROCICLICA A PARTIR DEL CALDO DE FERMENTACION. LOS COMPUESTOS PRODUCIDOS MEDIANTE ESTE PROCEDIMIENTO INCLUYEN UN COMPUESTO DE FORMULA (I). LA PRESENTE INVENCION TAMBIEN TRATA DE UNA COMPOSICION FARMACEUTICA QUE INCLUYE EL MISMO, QUE RESULTA UTIL COMO AGENTE INMUNOSUPRESOR, ANTIMICOTICO, ANTITUMORAL O SIMILARES.
ES95932876T 1994-11-10 1995-10-13 Compuestos de lactona macrociclica y su procedimiento de produccion. Expired - Lifetime ES2194054T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9401896 1994-11-10
PCT/IB1995/000870 WO1996015131A1 (en) 1994-11-10 1995-10-13 Macrocyclic lactone compounds and their production process

Publications (1)

Publication Number Publication Date
ES2194054T3 true ES2194054T3 (es) 2003-11-16

Family

ID=1341416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932876T Expired - Lifetime ES2194054T3 (es) 1994-11-10 1995-10-13 Compuestos de lactona macrociclica y su procedimiento de produccion.

Country Status (12)

Country Link
US (2) US6001998A (es)
EP (1) EP0854874B1 (es)
JP (1) JP3061863B2 (es)
AT (1) ATE239024T1 (es)
CA (1) CA2204739C (es)
DE (1) DE69530616T2 (es)
DK (1) DK0854874T3 (es)
ES (1) ES2194054T3 (es)
FI (1) FI971995A (es)
MX (1) MX9703484A (es)
PT (1) PT854874E (es)
WO (1) WO1996015131A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015131A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Macrocyclic lactone compounds and their production process
DE60229371D1 (de) * 2001-05-02 2008-11-27 Brni Neurosciences Inst Kohlensäureanhydrase-aktivatoren zur verbesserung der lern- und gedächtnisleistung
US6551591B1 (en) 2001-09-07 2003-04-22 Essential Therapeutics, Inc. Antibiotics from microbispora
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
CN1946656B (zh) * 2004-02-17 2011-08-24 托马斯·E·约翰逊 形成大环化合物的方法、组合物和设备
TW200538181A (en) * 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
CA2598805A1 (en) * 2005-02-24 2006-08-31 Biocern, Inc. Sperm cell separation methods and compositions
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
EP1915145A1 (en) 2005-07-29 2008-04-30 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
KR20090038478A (ko) 2006-07-28 2009-04-20 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 세포 성장 자극, 시냅스 리모델링 및 장기간 기억 강화 방법
AU2007289164A1 (en) * 2006-08-30 2008-03-06 Biocern, Inc. Sperm cell separation methods and compositions containing aptamers or nucleic acid sequences for use therein
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
JP6049160B2 (ja) * 2006-09-13 2016-12-27 エリクシアー メディカル コーポレイション 大環状ラクトン化合物およびその使用方法
EP2737904A3 (en) 2007-02-09 2014-12-17 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
KR20090119894A (ko) 2007-02-09 2009-11-20 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
JP5726171B2 (ja) * 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド E−セレクチンおよびcxcr4ケモカイン受容体のヘテロ二官能性阻害剤
WO2011026076A2 (en) * 2009-08-31 2011-03-03 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
WO2012006525A2 (en) 2010-07-08 2012-01-12 Alkon Daniel L Pkc activators and anticoagulant in regimen for treating stroke
WO2012024630A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
US10821079B2 (en) 2011-11-13 2020-11-03 Cognitive Research Enterprises, Inc. PKC activators and combinations thereof
US20180217163A1 (en) 2015-05-11 2018-08-02 Daniel L. Alkon Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
RU2629653C1 (ru) * 2016-03-21 2017-08-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Юго-Западный государственный университет " (ЮЗГУ) Мостовой измеритель параметров двухполюсников
CN107827803A (zh) * 2017-11-28 2018-03-23 绍兴厚普生物科技有限责任公司 一种从发酵液中提取l‑羟脯氨酸的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1910715A1 (de) * 1968-03-04 1969-10-09 Stanley Drug Products Inc Antimikrobielle Faktoren und deren Verwendung
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5674732A (en) * 1992-04-27 1997-10-07 Pfizer Inc. Rapamycin producer
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
WO1996015131A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Macrocyclic lactone compounds and their production process

Also Published As

Publication number Publication date
MX9703484A (es) 1997-08-30
DK0854874T3 (da) 2003-06-02
PT854874E (pt) 2003-07-31
JPH11507907A (ja) 1999-07-13
ATE239024T1 (de) 2003-05-15
EP0854874B1 (en) 2003-05-02
CA2204739C (en) 2000-04-04
WO1996015131A1 (en) 1996-05-23
FI971995A0 (fi) 1997-05-09
US6001998A (en) 1999-12-14
US6187568B1 (en) 2001-02-13
JP3061863B2 (ja) 2000-07-10
DE69530616D1 (de) 2003-06-05
DE69530616T2 (de) 2004-04-01
EP0854874A1 (en) 1998-07-29
FI971995A (fi) 1997-05-09

Similar Documents

Publication Publication Date Title
ES2194054T3 (es) Compuestos de lactona macrociclica y su procedimiento de produccion.
ES2185772T3 (es) Derivados de 1,3-propano-diol como compuestos bioactivos.
ES2152701T3 (es) Composiciones acuosas desinfectantes y de limpieza.
BR9608547A (pt) Método para melhorar a sa·de animal
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
BRPI0412386A (pt) método para melhorar a produtividade da planta, actinomiceto endofìtico, composição agrìcola, metabólitos, anticorpo, métodos para melhorar a produtividade das plantas, para facilitar a biodegradação de material biodegradável, e para tratar terapêutica e/ou profilaticamente de uma condição em um paciente, e, uso do actinomiceto ou dos metabólitos
AR002061A1 (es) Compuesto elastomerico que incorpora negro de carbon recubierto parcialmente, un articulo formado a partir de dicho compuesto, una formulacionque lo contiene y un metodo para mejorar la histeresis.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ES2125535T5 (es) Mezclas, que contienen isocianatos emulsionables en agua.
AR001931A1 (es) Compuesto de 7-acilamino-3-iminometil (sustituido)cefalosporinas un proceso para su producción intermediarios en su producción una composición farmacéutica que contiene tales compuestos su utilizacióncomo compuestos farmacéuticos y un método para tratar enfermedades microbianas mediante administración de tales compuestos
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
BR0304218A (pt) ésteres alicìclicos com fragrância de almìscar
ES2149931T3 (es) Procedimiento para la produccion de xilitol.
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.
DE69905700D1 (de) Desinfizierende Zusammensetzung
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
BR9506866A (pt) Composiçao biologicamente purificada composiçao para utilizaçao como um agente anti-inflamatório processo para o tratamento de mamíferos tendo tecido inflamado e processo para á produçao de ciclomarin-a
ES2109561T3 (es) Procedimiento para la depuracion de aguas destinadas al consumo humano.
UY26492A1 (es) Bencimidazoles, su preparación y su empleo como medicamentos.
ES2163634T3 (es) Benzopiranos y composiciones farmaceuticas que les contienen.
BRPI0507978A (pt) bactéria produtora de l-aminoácido pertencente à famìlia enterobacteriaceae, e, método para produzir um l-aminoácido
ES2169325T3 (es) Compuestos peptidos ciclicos para el tratamiento del dolor y procedimiento de produccion de los mismos.
ES2196171T3 (es) Agentes antitumorales de tioxantenona liofilizada.